Naphalon 0.005%+0.02% belongs to the generic category of Naphazoline + Zinc Sulfate. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Naphalon 0.005%+0.02%. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Naphazoline + Zinc Sulfate and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

*Up to 10% Discount
(Depends on pharmacy)
/ 10 ml drop
Naphalon 0.005%+0.02% may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Naphalon 0.005%+0.02% is provided below to help users gain a clear understanding of this medicine.
Acute and chronic non-infectious conjunctivitis, nonspecific conjunctival irritation; also after successful treatment of bacterial and viral conjunctivitis. Irrigation of the tear ducts.
Zinc ions, the active compound of zinc sulphate, have an astringent, i.e. tissue-sealing and slightly anti-septic effect. Naphazoline constricts the blood vessels and reduces the inflammation and swelling of the conjunctiva. This effect of naphazoline, a substance of the benzylimidazoline group, is due to direct binding to a-adrenergic receptor sites on unstriated muscle cells in the blood vessels.
Adults: 1 drop in the conjunctival sac, three to 4 times per day.Children: Naphazoline nitrate and Zinc sulphate drops has not been studied in children. Generally, in children the dosage of vasoconstrictors should be low and selected with caution.
Naphazoline containing products should not be administered during treatment with MAO-blockers nor during 10 days after discontinuation of such treatment. The effects of Naphazoline may be increased by concomitant use of tricyclic antidepressants.
Mydriasis and a slight increase of intraocular pressure in isolated cases. A slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. Long term use may result in reactive redness of the eye (rebound effect).In very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. Nonspecific fatigue has been observed in some patients.
Use in pregnancy: There are neither controlled animal studies nor studies in pregnant women available.Use in lactation: The effects of Naphazoline & Zinc treatment during lactation have not been investigated.
Uncontrolled use of Naphazoline & Zinc over extended periods of time should be avoided. If no improvement is seen after 2 days, treatment should be discontinued and other therapeutic measures should be considered. If ocular discomfort or visual disturbance occurs during Naphazoline & Zinc treatment, the therapy must be discontinued. Caution is indicated in patients with predisposition to glaucoma and in patients suffering from hypertension, cardiovascular diseases, pheochromocytoma, aneurysm, hyperglycemia, and hyperthyroidism.
Ophthalmic Non-Steroid drugs
Data Source: Data source of Indications and Usages, Pharmacology, Dosage & Administration, Drug Interactions, Side Effects, Use during Pregnancy & Lactation, Precautions & Warnings, Use in Special Populations, Therapeutic Class, and Storage Conditions is the concerned medicine company or respective organization.
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines

N:B-All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines"
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023